All In MedTech

Device Trial Radar · NCT03109964

The Affect of Hemostasis Technique During Laparoscopic Ovarian Cystectomy on Future Fertility

The Affect of Hemostasis With Bipolar Coagulation Versus SURGIFLO Placement on Ovarian Reserve and Future Fertility

Last checked: Nov 19, 2026Latest source record: Oct 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

Nov 20, 2018

Primary completion

Mar 31, 2021

Study completion Aug 1, 2022

Sponsor

Lead sponsor
Rambam Health Care CampusAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 12, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 18 years, up to 44 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients undergoing elective laparoscopic ovarian cystectomy will be recruited and randomly divided into 2 groups according to intervention technique-half will be allocated to the bipolar coagulation group and half to the SURGIFLO group. Patients will be assessed both pre-operatively and 6 months post-operatively by blood tests including follicle stimulating hormone (FSH), lutenizing hormone (LH), Estrogen (E2), Progesterone and anti-mullerian hormone (AMH) levels, and sonographic evaluation of ovarian volume and antral follicle count.

Conditions

  • Cyst Ovary

Interventions

  • Bipolar coagulation forceps (ETHICON inc.)Device

    Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.

  • SURGIFLO hemostatic matrix (ETHICON inc.)Device

    Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Decline in ovarian reserve.Time frame: Up to 6 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rambam health care campus

    Haifa, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.